General
Preferred name
FEBUXOSTAT
Synonyms
TEI-6720 ()
Febuxostat D9 ()
TEI 6720 ()
Uloric ()
FBX ()
TMX67 ()
TMX 67 ()
Febuxostat (TEI-6720) ()
TMX 67, TEI-6720 ()
NSC-758874 ()
TMX-67 ()
Adenuric ()
Febuxostat-d9 ()
P&D ID
PD009360
CAS
144060-53-7
1246819-50-0
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
2009
Drug Status
approved
Drug indication
Hyperuricaemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM Febuxostat is extensively metabolized by both conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 and 2C9 and non-P450 enzymes. The relative contribution of each enzyme isoform in the metabolism of febuxostat is not clear. The oxidation of the isobutyl side chain leads to the formation of four pharmacologically active hydroxy metabolites, all of which occur in plasma of humans at a much lower extent than febuxostat.; In urine and feces, acyl glucuronide metabolites of febuxostat (~35% of the dose), and oxidative metabolites, 67M-1 (~10% of the dose), 67M-2 (~11% of the dose), and 67M-4, a secondary metabolite from 67M-1 (~14% of the dose), appeared to be the major metabolites of febuxostat in vivo.
DESCRIPTION Inhibits xanthine dehydrogenase (GtoPdb)
DESCRIPTION ASK1 inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Xanthine oxidase inhibitor (Tocriscreen Plus)
Compound Sets
32
AdooQ Bioactive Compound Library
A10382
Axon Medchem Screening Library
1175
Cayman Chemical Bioactives
14127
25033
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1164729
ChEMBL Drugs
CHEMBL1164729
Concise Guide to Pharmacology 2017/18
6817
Concise Guide to Pharmacology 2019/20
6817
Concise Guide to Pharmacology 2021/22
6817
Concise Guide to Pharmacology 2023/24
6817
Drug Repurposing Hub
DrugBank
DB04854
DrugBank Approved Drugs
DB04854
DrugCentral
1137
DrugCentral Approved Drugs
1137
DrugMAP
DMDEXQ0
DrugMAP Approved Drugs
DMDEXQ0
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101709
Guide to Pharmacology
6817
LINCS compound set
10416-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1164729
MedChem Express Bioactive Compound Library
HY-14268
NCATS Inxight Approved Drugs
101V0R1N2E
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Febuxostat(Uloric)
TargetMol Bioactive Compound Library
T0773
The Spectrum Collection
Tocris Bioactive Compound Library
4427
Tocriscreen Plus
4427
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
316.09
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
3.72
TPSA
83.21
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.91
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
Xanthine oxidase
Xanthine dehydrogenase
XO
XDH
XO inhibitor
ROS
Pathway
Metabolic Enzyme/Protease
Immunology/Inflammation
MOA
xanthine dehydrogenase-oxidase inhibitor
Inhibitor
Xanthine Oxidase inhibitor
Primary Target
Other Oxygenases/Oxidases
Indication
hyperuricemia
Source data